Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study - Sunami, Kuniko; Ichikawa, Hitoshi; Kubo, Takashi; Kato, Mamoru; Fujiwara, Yutaka; Shimomura, Akihiko; Koyama, Takafumi; Kakishima, Hiroki; Kitami, Mayuko; Matsushita, Hiromichi; Furukawa, Eisaku; Narushima, Daichi; et al. (Cancer science, 2019)
Keywords: actionable gene aberration; Adult; Aged; Biomarkers, Tumor; Cancer; Cancer therapies; Clinical medicine; clinical sequencing; Clinical trials; Computational Biology - methods; Consent; Deoxyribonucleic acid; DNA; DNA Copy Number Variations; Drugs; Female; Gene Expression Profiling - methods; gene panel test; Genes; Genes, Neoplasm; Genetic counseling; Genomics; Genomics - methods; High-Throughput Nucleotide Sequencing; Hospitals; Humans; Impact tests; insurance reimbursement; Laboratories; Male; Middle Aged; Molecular Targeted Therapy; Mutation; NCC Oncopanel; Neoplasms - diagnosis; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - mortality; Next-generation sequencing; Oncology; Original; Patients; Physicians; Prognosis; R&D; Research & development; Solid tumors; Studies; Treatment Outcome; Tumors; United States--US; Japan; clinical sequencing; NCC Oncopanel; gene panel test; actionable gene aberration; insurance reimbursement